Tune Therapeutics
Tune Therapeutics develops TEMPO, an epigenomic platform that fine-tunes gene activity without altering DNA. It is developing therapies for chronic hepatitis B, rare single-gene disorders and other conditions.
Facts
- HQ
- Seattle, Washington, USA and Durham, North Carolina, USA
- Sectors
- Biotechnology, Therapeutics, Epigenomics
- Stage
- Series B
- Members see funding amounts. .
Is this your organization? Claim it
Reed Jobs’s Yosemite closes $350 million second fund to pursue making cancer non-lethal
Reed Jobs’s venture firm Yosemite closed a $350 million second fund to back cancer-focused startups and grants with the stated goal of transforming cancer into a non-lethal disease rather than curing it outright. Jobs, who began cancer research as a teenager after his father’s illness, has LPs including Amgen, AbbVie, MIT, Memorial Sloan Kettering, and John Doerr.
Blue Origin's New Glenn Rocket Achieves First Orbital Launch Amid Schedule Hiccups; Microsoft Creates New AI Division Led by Ex-Facebook Chief; Truveta Raises $320M for Genome Initiative
Jeff Bezos' Blue Origin faced multiple scheduling changes before successfully launching its heavy-lift New Glenn rocket to orbit for the first time. Additionally, Microsoft established a new AI division led by a former Facebook engineering chief, and Seattle's Truveta secured $320 million to start a large genome project.
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
See all 6 stories, episodes and videos about Tune Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events